Johns Hopkins Drug Discovery - Course - Drug Discovery Case Studies
page-template,page-template-full_width,page-template-full_width-php,page,page-id-90,page-child,parent-pageid-25,ajax_fade,page_not_loaded,,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-4.12.1,vc_responsive

Drug Discovery Case Studies (ME:200.707)

“Drug Discovery Case Studies” is designed to provide students with insights into the ever-changing landscape of drug discovery research by presenting case studies for various breakthrough drugs discovered since the 1940s. Each lecture selects a particular drug that has made a significant impact on patients’ lives and examines some key elements that have contributed to its successful discovery and development. The course is given by the lecturers that participated in “Introduction to Drug Discovery Research”. The final three lectures will be given by guest speakers who will present case studies on new drugs in which they were directly involved at the time of discovery and development.

Fall 2018
Course Director: Takashi Tsukamoto (
Location: Rangos Building Room 590
Time: 10:00 AM – 11:30 AM
Dates: Every Friday 9/7/2018-12/14/2018


No prior knowledge in drug discovery is required. This course is recommended for students in the 2nd or later year of their graduate program.

Grades will be determined by:

Lecture report: Students will select one lecture from the course and write a report describing how they would give a lecture on the same drug (e.g., different aspects to be covered, inaccuracy and/or critical facts missing from the lecture, etc.). Grade weights: 40%.

Group project: 5-6 Students will form a team to prepare a case study presentation on a drug selected from a list provided by the course director. The grade will be determined by the students’ presentation on the project. Grade weights: 60%.

All students with disabilities who require accommodations for this course should contact Catherine L. Will, Disability Services Coordinator for Graduate Biomedical Education ( or 410-614-3781) at their earliest convenience to discuss their specific needs. Please note that accommodations are not retroactive.


Course Schedule

Topic Lecturer
9/7 Introduction Takashi Tsukamoto
9/14 Penicillin Takashi Tsukamoto
9/21 Methotrexate Kathryn Lemberg
9/28 Propranolol Jim Barrow
10/5 Captopril David Meyers
10/12 Palonosetron Camilo Rojas
10/19 Etelcalcetide (Parsabiv®) Les Miranda (Amgen)
10/26 Aripiprazole  Takashi Tsukamoto
11/2 Durvalumab (Imfinzi®)  Scott Hammond (MedImmune)
11/9 Suvorexant (Belsomra®)  Anthony Roecker (Merck)
11/16 Group Discussion Students
11/30, 12/7, 12/14 Project Presentation Students

 Past Guest Lectures

Topic Lecturer
10/31/12 Eribulin Bruce Littlefield (Eisai)*
 11/7/12  Denosumab  Scott Simonet (Amgen)*
 11/14/12  Raltegravir  Steve Young (formerly at Merck)*
 10/29/14  Tafacitinib Chakrapani Subramanyam (Pfizer)
 11/5/14 Trastuzumab emtansine  Gail Phillips (Genentech)
 11/12/14 Linaclotide Caroline Kurtz (Ironwood Pharma)
 10/28/16  Ledipasvir/Sofosbuvir (Harvoni®)  Michael Sofia (Arbutus Biopharma, Inc.)
 11/4/16  Mepolizumab (Nucala®)  Steven Yancey (GlaxoSmithKline)
 11/11/16  Lumacaftor/Ivacaftor (Orkambi®)  Mark Miller (Vertex Pharmaceuticals Inc.)

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.